fatty acid oxidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Ripasudil had no effect on respiratory or neurological function. Although no carcinogenicity studies were performed on the drug, developers believed it to be non-carcinogenic due to its rapid elimination and therefore lack of accumulation in tissue, as well as the lack of inflammatory response in the eye post-administration.
=== Bacteria === Brine pockets are home to a diverse and dynamic community of marine bacteria which are adapted to survive and thrive in the extreme cold, called psychrophiles. As psychrophiles are adapted to survive and grow at very low temperatures, they are capable of synthesizing enzymes that remain active at low temperatures, allowing them to metabolize in the extremely cold conditions of brine pockets and channels. Bacteria in brine pockets must also be able to tolerate high salt concentrations, so these bacteria are also halophilic. Halophilic psychrophiles are found within Proteobacteria, Actinobacteria and Bacteroidetes. Two Proteobacteria found to be abundant in brine pockets are gammaproteobacteria and alphaproteobacteria. Many gammaproteobacteria are capable of degrading organic matter, making them important for nutrient cycling and organic matter turnover within the brine pocket. For example, aerobic anoxygenic phototrophic (AAP) bacteria are found in marine environments and play a vital role in supporting the electron transport chain by metabolizing bacteriochlorophyll. Alphaproteobacteria include species that are known to be important for nitrogen cycling and carbon cycling in marine environments. Some Alphaproteobacteria are capable of nitrogen fixation, which can provide an important source of nitrogen for other microorganisms within the pocket.
=== Management buyout and retro theming (1995–2001) === In 1995, the chain was bought from Unilever by senior management. During 1997 and 1998, Drew Carey served as a spokesperson for the chain, appearing in TV ads alongside the Great Root Bear; he was dismissed (with legal action ensuing) after a November 1998 episode of The Drew Carey Show featured Carey eating at a McDonald's location in China.
Octreotide (brand name Sandostatin, Novartis Pharmaceuticals) is an octapeptide that mimics natural somatostatin pharmacologically, though is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone, and has a much longer half-life (about 90 minutes, compared to 2–3 minutes for somatostatin). Since it is absorbed poorly from the gut, it is administered parenterally (subcutaneously, intramuscularly, or intravenously). It is indicated for symptomatic treatment of carcinoid syndrome and acromegaly. It is also finding increased use in polycystic diseases of the liver and kidney. Lanreotide (Somatuline, Ipsen Pharmaceuticals) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analog of somatostatin, like octreotide. It is available in several countries, including the United Kingdom, Australia, and Canada, and was approved for sale in the United States by the Food and Drug Administration on August 30, 2007. Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
=== Acute toxicity === Although a low dosis of arenobufagin can be used as a medicine to treat heart rate problems, a high dose can lead to acute heart problems and even death. Arenobufagin is also toxic for hepatocellular carcinoma cells, which is a positive result for the body.
Sources: en.wikipedia.org
=== Pattern-based measures === Earlier methods for measuring convergence incorporate ratios of phenotypic and phylogenetic distance by simulating evolution with a Brownian motion model of trait evolution along a phylogeny. More recent methods also quantify the strength of convergence. One drawback to keep in mind is that these methods can confuse long-term stasis with convergence due to phenotypic similarities. Stasis occurs when there is little evolutionary change among taxa. Distance-based measures assess the degree of similarity between lineages over time. Frequency-based measures assess the number of lineages that have evolved in a particular trait space.
On the same day the ICJ's ruling was made public, South African prime minister B. J. Vorster rejected it as "politically motivated", with no foundation in fact. However, the decision inspired the bishops of the Evangelical Lutheran Ovambo-Kavango Church to draw up an open letter to Vorster denouncing apartheid and South Africa's continued rule. This letter was read in every black Lutheran congregation in the territory, and in a number of Catholic and Anglican parishes elsewhere. The consequence of the letter's contents was increased militancy on the part of the black population, especially among the Ovambo people, who made up the bulk of SWAPO's supporters. Throughout the year there were mass demonstrations against the South African government held in many Ovamboland schools. In December 1971, Jannie de Wet, Commissioner for the Indigenous Peoples of South West Africa, sparked off a general strike by 15,000 Ovambo workers in Walvis Bay when he made a public statement defending the territory's controversial contract labour regulations. The strike quickly spread to municipal workers in Windhoek, and from there to the diamond, copper and tin mines, especially those at Tsumeb, Grootfontein, and Oranjemund. Later in the month, 25,000 Ovambo farm labourers joined what had become a nationwide strike affecting half the total workforce. The South African police responded by arresting some of the striking workers and forcibly deporting the others to Ovamboland.
mosaicism The presence of two or more populations of cells with different genotypes in an individual organism which has developed from a single fertilized egg. A mosaic organism can result from many kinds of genetic phenomena, including nondisjunction of chromosomes, endoreduplication, or mutations in individual stem cell lineages during the early development of the embryo. Mosaicism is similar to but distinct from chimerism.
=== Toxicity and adverse effects === Adverse effects of polyphenol intake range from mild (e.g., gastrointestinal tract symptoms) to severe (e.g., hemolytic anemia or liver failure). In 1988, hemolytic anemia following polyphenol consumption was documented, resulting in the withdrawal of a catechin-containing drug. Polyphenols, particularly in beverages that contain them in high concentrations (tea, coffee, etc), inhibit the absorption of non-haem iron when consumed together in a single meal. Research is limited on the effect of this inhibition on iron status. Metabolism of polyphenols can result in flavonoid-drug interactions, such as in grapefruit–drug interactions, which involves inhibition of the liver enzyme, CYP3A4, likely by grapefruit furanocoumarins, a class of polyphenol. The European Food Safety Authority established upper limits for some polyphenol-containing supplements and additives, such as green tea extract or curcumin. For most polyphenols found in the diet, an adverse effect beyond nutrient-drug interactions is unlikely.
Scholarly descriptions of what would now be recognized as dinosaur bones first appeared in the late 17th century in England. Part of a bone, now known to have been the femur of a Megalosaurus, was recovered from a limestone quarry at Cornwell near Chipping Norton, Oxfordshire, in 1676. The fragment was sent to Robert Plot, Professor of Chemistry at the University of Oxford and first curator of the Ashmolean Museum, who published a description in his The Natural History of Oxford-shire (1677). He correctly identified the bone as the lower extremity of the femur of a large animal, and recognized that it was too large to belong to any known species. He therefore concluded it to be the femur of a huge human, perhaps a Titan or another type of giant featured in legends. Edward Lhuyd, a friend of Sir Isaac Newton, published Lithophylacii Britannici ichnographia (1699), the first scientific treatment of what would now be recognized as a dinosaur. In it he described and named a sauropod tooth, "Rutellum impicatum", that had been found in Caswell, near Witney, Oxfordshire.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.